financetom
Business
financetom
/
Business
/
Why Hims & Hers Health Stock Is Rising Today
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Hims & Hers Health Stock Is Rising Today
May 7, 2024 10:51 AM

Hims and Hers Health Inc. ( HIMS ) shares are up Tuesday after the company reported better-than-expected first quarter financial results.

The Details: After the market close on Monday, Hims & Hers Health ( HIMS ) reported strong first-quarter results that included revenue of $278.2 million, representing a 46% increase from $190.8 million in the first quarter of 2023. The number beat analyst estimates of $270.382 million.

The company posted net income of $11.1 million and EPS of 5 cents, beating EPS estimates of 2 cents by 150%.

In addition, Hims & Hers Health ( HIMS ) reported adjusted EBITDA of $32.3 million for the first quarter compared to $6.1 million in the first quarter of 2023.

“The business continues to generate robust performance across our operations as we execute on our mission to make the world feel great through the power of better health,” said Yemi Okupe, CFO of Hims & Hers Health ( HIMS ).

The company saw 41% year-over-year growth in subscribers during the quarter, bringing total subscribers up to 1.7 million.

Hims & Hers Health ( HIMS ) also issued guidance for the second quarter. The company expects revenue of $292 million to $297 million versus estimates of $288.073 million. Hims & Hers Health ( HIMS ) also sees adjusted EBITDA between $30 million and $35 million.

For the full fiscal year, the company expects revenue of $1.20 billion to $1.23 billion versus estimates of $1.191 billion.

Related Link: 12 Health Care Stocks Moving in Monday’s After-Market Session.

On Tuesday, Piper Sandler maintained a Neutral rating on the stock and raised the price target from $11 to $13. Deutsche Bank also maintained Hims & Hers Health ( HIMS ) with a Hold rating and raised the price target from $14 to $16.

Price Action: According to Benzinga Pro, Hims & Hers Health ( HIMS ) shares were up 7.25% at $12.48 at the time of publication.

Image: Courtesy of Hims & Hers Health, Inc. ( HIMS )

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Canadian Imperial Bank of Commerce to Hire Over 200 Data, AI Roles
Canadian Imperial Bank of Commerce to Hire Over 200 Data, AI Roles
Aug 6, 2024
10:32 AM EDT, 08/06/2024 (MT Newswires) -- Canadian Imperial Bank of Commerce ( CM ) said Tuesday it intends to hire more than 200 data and artificial intelligence roles. The company said it will add the roles over the next 12 months. The company's shares were up 1.6% in recent trading. Price: 49.22, Change: +0.79, Percent Change: +1.63 ...
Bicycle Therapeutics Q2 Net Loss Narrows, Revenue Lower
Bicycle Therapeutics Q2 Net Loss Narrows, Revenue Lower
Aug 6, 2024
10:31 AM EDT, 08/06/2024 (MT Newswires) -- Bicycle Therapeutics ( BCYC ) reported Q2 net loss Tuesday of $0.77 per diluted share, narrowing from a loss of $1.41 a year earlier. Analysts polled by Capital IQ expected a loss of $1.12. Revenue for the quarter fell to $9.36 million from $11.4 million a year ago. Analysts polled by Capital IQ...
General Motors Unusual Options Activity For August 06
General Motors Unusual Options Activity For August 06
Aug 6, 2024
Financial giants have made a conspicuous bullish move on General Motors ( GM ). Our analysis of options history for General Motors ( GM ) revealed 8 unusual trades. Delving into the details, we found 37% of traders were bullish, while 37% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $154,945,...
Listerine-Maker Kenvue's Stock Soars On Strong Q2 Sales From Its Essential Health Unit, Reaffirms Annual Guidance
Listerine-Maker Kenvue's Stock Soars On Strong Q2 Sales From Its Essential Health Unit, Reaffirms Annual Guidance
Aug 6, 2024
Consumer health company Kenvue Inc. ( KVUE ) stock is trading higher after the company reported better-than-expected second-quarter 2024 financial results. The Johnson & Johnson consumer spin-off reported sales of $4 billion, down 0.3% year-over-year (up 1.5% organically), beating the consensus of $3.94 billion. Kenvue’s some of the iconic brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. Value realization...
Copyright 2023-2026 - www.financetom.com All Rights Reserved